Cell composition and expansion strategy can reduce the beneficial effect of AKT-inhibition on functionality of CD8
AKT
Memory
Polyfunctionality
T cell
Th1
Th2
Journal
Cancer immunology, immunotherapy : CII
ISSN: 1432-0851
Titre abrégé: Cancer Immunol Immunother
Pays: Germany
ID NLM: 8605732
Informations de publication
Date de publication:
Nov 2020
Nov 2020
Historique:
received:
28
11
2019
accepted:
15
05
2020
pubmed:
7
6
2020
medline:
23
10
2020
entrez:
7
6
2020
Statut:
ppublish
Résumé
AKT-inhibition is a promising approach to improve T cell therapies; however, its effect on CD4
Identifiants
pubmed: 32504246
doi: 10.1007/s00262-020-02612-w
pii: 10.1007/s00262-020-02612-w
pmc: PMC7568704
doi:
Substances chimiques
1,3-dihydro-1-(1-((4-(6-phenyl-1H-imidazo(4,5-g)quinoxalin-7-yl)phenyl)methyl)-4-piperidinyl)-2H-benzimidazol-2-one
0
Benzimidazoles
0
Quinoxalines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2259-2273Subventions
Organisme : KWF Kankerbestrijding
ID : KUN2014-6716
Références
Immunity. 2017 Nov 21;47(5):848-861.e5
pubmed: 29126798
Immunity. 2005 Mar;22(3):371-83
pubmed: 15780993
Clin Cancer Res. 2011 Aug 15;17(16):5343-52
pubmed: 21737507
Oncoimmunology. 2018 Aug 6;7(10):e1488565
pubmed: 30288356
Nat Med. 2018 May;24(5):563-571
pubmed: 29713085
PLoS One. 2013 May 23;8(5):e63933
pubmed: 23717511
Nat Commun. 2012 Jul 10;3:948
pubmed: 22781761
J Clin Oncol. 2017 Jun 1;35(16):1803-1813
pubmed: 28291388
Sci Immunol. 2018 Jan 19;3(19):
pubmed: 29352091
Cell Metab. 2017 Mar 7;25(3):593-609
pubmed: 28190771
Proc Natl Acad Sci U S A. 2008 Jun 3;105(22):7797-802
pubmed: 18509048
JCI Insight. 2017 Apr 20;2(8):
pubmed: 28422756
Sci Transl Med. 2014 Feb 19;6(224):224ra25
pubmed: 24553386
Adv Exp Med Biol. 2014;841:45-65
pubmed: 25261204
Cell Rep. 2016 Jan 26;14(3):586-597
pubmed: 26774484
JCI Insight. 2017 Mar 9;2(5):e90772
pubmed: 28289713
J Clin Invest. 2016 Sep 1;126(9):3363-76
pubmed: 27482888
Oncol Lett. 2018 Jul;16(1):875-881
pubmed: 29963158
N Engl J Med. 2014 Oct 16;371(16):1507-17
pubmed: 25317870
J Clin Oncol. 2016 Apr 1;34(10):1112-21
pubmed: 26811520
Lancet. 2015 Feb 7;385(9967):517-528
pubmed: 25319501
J Clin Invest. 2013 Feb;123(2):594-9
pubmed: 23281401
Leukemia. 2016 Feb;30(2):492-500
pubmed: 26369987
Sci Transl Med. 2011 Aug 10;3(95):95ra73
pubmed: 21832238
Science. 1992 Jul 24;257(5069):548-51
pubmed: 1636093
Cancer Res. 2015 Jan 15;75(2):296-305
pubmed: 25432172
J Immunol. 2018 Apr 15;200(8):2563-2570
pubmed: 29531163
Immunity. 2010 Jun 25;32(6):743-53
pubmed: 20620941
PLoS One. 2013 Nov 14;8(11):e80063
pubmed: 24244610
Cancer Res. 2012 Mar 1;72(5):1059-63
pubmed: 22253231
Immunity. 2016 Nov 15;45(5):1148-1161
pubmed: 27851915
J Immunol Res. 2018 Mar 19;2018:3530148
pubmed: 29750176
Nat Immunol. 2011 Apr;12(4):295-303
pubmed: 21358638
Blood. 2011 Dec 1;118(23):6050-6
pubmed: 21984804
Blood. 2014 Nov 27;124(23):3490-500
pubmed: 25336630
Blood. 2014 Jun 12;123(24):3750-9
pubmed: 24782509
Cancer Res. 2016 Dec 1;76(23):6864-6876
pubmed: 27634753
Cancer Immunol Res. 2014 Feb;2(2):91-8
pubmed: 24778273
Sci Transl Med. 2015 Sep 2;7(303):303ra139
pubmed: 26333935
JCI Insight. 2017 Dec 7;2(23):
pubmed: 29212954
J Clin Invest. 2016 Jan;126(1):318-34
pubmed: 26657860
Cancer Immunol Immunother. 2018 Jul;67(7):1053-1066
pubmed: 29605883
Nat Immunol. 2010 Jul;11(7):618-27
pubmed: 20467422
J Exp Med. 2011 Aug 29;208(9):1875-87
pubmed: 21825017
Sci Immunol. 2018 Jul 20;3(25):
pubmed: 30030369
J Exp Med. 2011 Mar 14;208(3):469-78
pubmed: 21339327
J Immunother Cancer. 2017 Mar 21;5:26
pubmed: 28331616
Annu Rev Immunol. 2010;28:445-89
pubmed: 20192806
Blood Adv. 2018 Feb 13;2(3):210-223
pubmed: 29386194
Oncoimmunology. 2015 Feb 3;4(5):e1005448
pubmed: 26155399
Proc Natl Acad Sci U S A. 2013 Jan 29;110(5):E415-24
pubmed: 23271806